FCMI
FBRX icon

Foresite Capital Management III’s Forte Biosciences FBRX Stock Holding History

Foresite Capital Management III’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,515
Closed -$3.79M – 15
2019
Q2 		$3.79M Hold
1,515
– – 1.24% 15
2019
Q1 		$6.17M Sell
1,515
-259
-15% -$1M 1.61% 15
2018
Q4 		$5.46M Buy
1,774
+1,378
+348% +$5.93M 1.79% 14
2018
Q3 		$2.32M Hold
396
– – 0.51% 22
2018
Q2 		$1.39M Hold
396
– – 0.3% 22
2018
Q1 		$1.76M Hold
396
– – 0.38% 21
2017
Q4 		$1.52M Sell
396
-386
-49% -$1.54M 0.43% 16
2017
Q3 		$3.65M Sell
782
-1,226
-61% -$5.46M 1.01% 19
2017
Q2 		$9.06M Buy
+2,008
New +$11.3M 2.96% 9

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Foresite Capital Management III's FBRX Position: Q3 2019 in Review

Foresite Capital Management III sold out of Forte Biosciences (FBRX) in Q3 2019, closing a stake of 1,515 shares — an estimated $3.79M sold.

Foresite Capital Management III first reported a position in FBRX in Q2 2017 and held it in 9 quarters. The position peaked at $9.06M in Q2 2017. 58 funds tracked by Wall St. Rank hold FBRX as of Q3 2019.

  • Foresite Capital Management III reported no remaining Forte Biosciences position as of Q3 2019 after selling out during the quarter.
  • Foresite Capital Management III sold 1,515 Forte Biosciences shares in Q3 2019, an estimated $3.79M.
  • Foresite Capital Management III first reported a position in Forte Biosciences in Q2 2017 and held it in 9 quarters.
  • Foresite Capital Management III's Forte Biosciences position peaked at $9.06M in Q2 2017.
  • 58 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2019.

Based on Foresite Capital Management III's 13F filing for Q3 2019, filed 13 Nov 2019.